- Conditions
- Hepatitis C, Hepatitis C, Chronic
- Interventions
- Eligibility Screening, HCV test
- Other · Diagnostic Test
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 72 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 745
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Atopic Dermatitis
- Interventions
- delgocitinib
- Drug
- Lead sponsor
- LEO Pharma
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 9 more
- Conditions
- Sickle Cell Disease, Stroke, Neurologic Manifestations, Neurological Morbidity, Sickle Cell Anemia in Children, Sickle Cell Anemia
- Interventions
- This study does not entail offering any intervention; all data collected will be based on standard of care.
- Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 5 Years to 26 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Neurofibromatosis 1, Neurofibroma, Plexiform
- Interventions
- Medication Event Monitoring System (MEMS^TM), Questionnaires
- Behavioral · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 3 Years to 59 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Solid Tumors Harboring NTRK Fusion
- Interventions
- BAY2757556 (Larotrectinib, Vitrakvi)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 215 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 18
- States / cities
- Palo Alto, California • Santa Monica, California • Pembroke Pines, Florida + 13 more
- Conditions
- Sickle Cell Disease
- Interventions
- L-citrulline, Placebo
- Drug · Other
- Lead sponsor
- Asklepion Pharmaceuticals, LLC
- Industry
- Eligibility
- 6 Years to 21 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 6
- States / cities
- Washington D.C., District of Columbia • Coral Gables, Florida • Atlanta, Georgia + 3 more
- Conditions
- Anaplastic Astrocytoma, Diffuse Brainstem Glioma, Glioblastoma Multiforme, High-grade Astrocytoma NOS, Fibrillary Astrocytoma, Low-Grade Astrocytoma, Nos, Pilocytic Astrocytoma, Choroid Plexus Carcinoma, CNS Primary Tumor, Nos, Atypical Teratoid/Rhabdoid Tumor, Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, Ependymoma, NOS, Anaplastic Oligodendroglioma, Oligodendroglioma, Nos, CNS Germ Cell Tumor, Pineoblastoma, Diffuse Leptomeningeal Glioneuronal Tumor
- Interventions
- Not listed
- Lead sponsor
- Pediatric Brain Tumor Consortium
- Network
- Eligibility
- Up to 40 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 6 more
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, FSGS, MCD
- Interventions
- Biospecimen collection, Data collection
- Other
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- Not listed
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Asthma in Children
- Interventions
- Exercise Training
- Other
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 8 Years to 35 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- NF1, Low-grade Glioma
- Interventions
- Poly ICLC
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- Up to 22 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 7 more
- Conditions
- Pompe Disease
- Interventions
- respiratory muscle strength training
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 3 Years to 99 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, Lymphoma
- Interventions
- Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG), Stem Cell Transplant, Stem Cells Collections, Fludarabine, Thiotepa, Antithymocyte globulin (ATG), and Total Body Irradiation (TBI), Fludarabine, Busulfan, and ATG
- Drug · Procedure
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2018
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Chordoma
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Type 1 Diabetes, Celiac Disease
- Interventions
- Blood Draw
- Other
- Lead sponsor
- AdventHealth Translational Research Institute
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Adult ADHD
- Interventions
- Concerta
- Drug
- Lead sponsor
- University of Maryland, College Park
- Other
- Eligibility
- Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Fairfax, Virginia
- Conditions
- Autism Spectrum Disorder
- Interventions
- Not listed
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 186 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 6 more
- Conditions
- Attention-deficit/Hyperactivity Disorder, Autism Spectrum Disorder
- Interventions
- Methylphenidate extended-release liquid formulation
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- COVID-19, SARS-CoV-2, Inflammatory Bowel Diseases
- Interventions
- Not listed
- Lead sponsor
- Connecticut Children's Medical Center
- Other
- Eligibility
- 2 Years to 27 Years
- Enrollment
- 472 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Hartford, Connecticut
- Conditions
- Lymphoproliferative Disorder
- Interventions
- rituximab, cyclophosphamide, methylprednisolone, prednisone
- Biological · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2013
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 58 more
- Conditions
- Epilepsy
- Interventions
- Keppra XR
- Drug
- Lead sponsor
- UCB BIOSCIENCES, Inc.
- Industry
- Eligibility
- 12 Years to 55 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 6
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 3 more
- Conditions
- Autism Spectrum Disorder, Gastrointestinal Disorder
- Interventions
- Vancomycin, MoviPrep, Full Spectrum Microbiota
- Drug · Biological
- Lead sponsor
- Arizona State University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Tuberous Sclerosis Complex
- Interventions
- Basimglurant with crossover to Placebo, Placebo with crossover to Basimglurant
- Drug
- Lead sponsor
- Noema Pharma AG
- Industry
- Eligibility
- 5 Years to 30 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 6 more
- Conditions
- Macrophage Activation Syndrome, Primary Hemophagocytic Lymphohistiocytosis
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Month to 120 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- B-Acute Lymphoblastic Leukemia, CAR-T Cell Therapy, Cytokine Release Syndrome, Immune Effector Cell Associated Neurotoxicity Syndrome, Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome
- Interventions
- Anakinra (Kineret®)
- Drug
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Other
- Eligibility
- 1 Year to 25 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Chicago, Illinois